Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05348356 · ClinicalTrials.gov registry record · Phase 2
Nirogacestat in Ovarian Granulosa Cell Tumors
A Phase 2 study, sponsored by SpringWorks Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT05348356 is a Phase 2 study that has completed, run by SpringWorks Therapeutics. The registered enrollment target is 53 participants.
The verdict
NCT05348356, a Phase 2 study, has completed, sponsored by SpringWorks Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.
Interventions
- DRUG Nirogacestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2025-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05348356
The ClinicalTrials.gov registry entry for NCT05348356 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SpringWorks Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nirogacestat is the first listed.
NCT05348356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05348356 about?
NCT05348356 is a clinical study titled "Nirogacestat in Ovarian Granulosa Cell Tumors". This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.
What is the current status of trial NCT05348356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2022-08-30. Estimated completion is 2025-07-14.
What interventions are being tested in trial NCT05348356?
The interventions under investigation include: Nirogacestat (DRUG).
Who is sponsoring clinical trial NCT05348356?
This trial is sponsored by SpringWorks Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.